Diana Montgomery

Most-cited papers

1. Clinical improvement in psoriasis with specific targeting of interleukin-23

   T. Kopp, E. Riedl, C. Bangert, E. Bowman +14 more

   2015Nature214 citations

   Semantic Scholar

   Save

2. A Phase 1 Randomized, Double‐Blind, Placebo‐Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK‐1654 in Healthy Adults

   Antonios O. Aliprantis, Dennis G. Wolford, L. Caro, Brian M. Maas +11 more

   2020Clinical pharmacology in drug development63 citations

   Semantic Scholar

   Save

3. Pharmacokinetics of Tildrakizumab (MK‐3222), an Anti‐IL‐23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects

   Sauzanne G Khalilieh, P. Hodsman, Christine R. Xu, A. Tzontcheva +2 more

   2018Basic & Clinical Pharmacology & Toxicology36 citations

   Semantic Scholar

   Save

4. Effect of tildrakizumab (MK‐3222), a high affinity, selective anti‐IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis

   Sauzanne G Khalilieh, Azher Hussain, Diana Montgomery, Vanessa Levine +8 more

   2018British Journal of Clinical Pharmacology32 citations Open access

   Semantic Scholar

   Save

5. Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab

   A. B. Kimball, T. Kerbusch, F. van Aarle, P. Kulkarni +5 more

   2019British Journal of Dermatology27 citations Open access

   Semantic Scholar

   Save

6. Evaluation of the binding orientations of testosterone in the active site of homology models for CYP2C11 and CYP2C13.

   Hong-Wu Wang, J. D. Cheng, Diana Montgomery, K. Cheng

   2009Biochemical Pharmacology27 citations

   Semantic Scholar

   Save

7. Tildrakizumab, a novel anti-IL-23 monoclonal antibody, is unaffected by ethnic variability in Caucasian, Chinese, and Japanese subjects.

   A. Zandvliet, S. Glasgow, A. Horowitz, Diana Montgomery +5 more

   2015International journal of clinical pharmacology and therapeutics24 citations

   Semantic Scholar

   Save

8. Clinical Immunogenicity Risk Assessment for a Fusion Protein

   Gizette Sperinde, Diana Montgomery, D. Mytych

   2020AAPS Journal23 citations

   Semantic Scholar

   Save

9. Quantitative PCR assay for cytochromes P450 2B and 3A induction in rat precision-cut liver slices: correlation study with induction in vivo.

   Xiaoming Cui, A. Thomas, Yi Han, J. Palamanda +4 more

   2005Journal of pharmacological and toxicological methods23 citations

   Semantic Scholar

   Save

10. Implementing a Clinical Immunogenicity Strategy using Preclinical Risk Assessment Outputs.

    V. Jawa, Jad Maamary, Michael Swanson, Shuli Zhang +1 more

    2022Journal of Pharmacy and Science20 citations

    Semantic Scholar

    Save

11. Potent Bispecific Neutralizing Antibody Targeting Glycoprotein B and the gH/gL/pUL128/130/131 Complex of Human Cytomegalovirus

    Hang Su, Xiaohua Ye, D. Freed, Lei-Ke Li +12 more

    2020Antimicrobial Agents and Chemotherapy20 citations Open access

    Semantic Scholar

    Save

12. Assessment of Temporal Biochemical and Gene Transcription Changes in Rat Liver Cytochrome P450: Utility of Real-Time Quantitative RT-PCR

    F. Goodsaid, J. Palamanda, Diana Montgomery, George Mandakas +10 more

    2003Pharmaceutical Research15 citations

    Semantic Scholar

    Save

13. Development of a high-throughput in vitro assay using a novel Caco-2/rat hepatocyte system for the prediction of oral plasma area under the concentration versus time curve (AUC) in rats.

    K.-C. Cheng, Cheng Li, Y. Hsieh, Diana Montgomery +2 more

    2006Journal of pharmacological and toxicological methods9 citations

    Semantic Scholar

    Save

14. Clinical Immunogenicity Risk Assessment Strategy for a Low Risk Monoclonal Antibody

    R. Kernstock, Gizette Sperinde, D. Finco, Roslyn Davis +1 more

    2020AAPS Journal8 citations

    Semantic Scholar

    Save

15. Nonclinical safety of tildrakizumab, a humanized anti-IL-23p19 monoclonal antibody, in nonhuman primates.

    M. Santostefano, D. Herzyk, Diana Montgomery, J. Wolf

    2019Regulatory toxicology and pharmacology : RTP7 citations

    Semantic Scholar

    Save

16. Rat PXR reporter-gene activity correlates with the induction of CYP3A in rat precision-cut liver slices.

    Xiaoming Cui, A. Thomas, Diana Montgomery, C. Gu +3 more

    2005Combinatorial chemistry & high throughput screening6 citations

    Semantic Scholar

    Save

17. Assessment of Bezlotoxumab Immunogenicity

    Diana Montgomery, R. P. Matthews, Ka L. Yee, L. Tobias +2 more

    2020Clinical pharmacology in drug development3 citations

    Semantic Scholar

    Save

18. How many people develop anti‐drug antibodies to the biologic drug tildrakizumab, and what impact does this have on the effectiveness of their treatment

    A. Kimball, T. Kerbusch, F. van Aarle, P. Kulkarni +5 more

    20201 citations Open access

    Semantic Scholar

    Save

19. 有多少人开发生物制剂 tildrakizumab 的抗药抗体, 以及这对其治疗有效性产生哪些影响

    A. B. Kimball, T. Kerbusch, F. van Aarle, P. Kulkarni +5 more

    20200 citations Open access

    Semantic Scholar

    Save

20. Protein drug-drug interactions for therapeutic modalities

    Li-Ming Liu, R. Evers, Diana Montgomery

    20200 citations

    Semantic Scholar

    Save

21. A Rising Multiple-Dose Tolerability, Safety, and Pharmacokinetic Study of Intravenous Tildrakizumab in Patients With Psoriasis

    A. Mehta, T. Kopp, E. Riedl, C. Bangert +14 more

    20150 citations Open access

    Semantic Scholar

    Save